Price Chart

Executive Summary

XOMA Royalty filed its definitive proxy statement on Schedule 14A, setting a special stockholder meeting for July 13, 2026 to approve the all-cash acquisition by Ligand Pharmaceuticals. Stockholders will receive $39.00 per share plus one contingent value right (CVR) tied to the Janssen litigation, with the board and holders of >44% of voting shares already committed to vote in favor. The merger is expected to close in Q3 2026, after which XOMA's common stock (XOMA) and preferred stock (XOMAP, XOMAO) will be delisted and the perpetual preferred shares redeemed.

Key Financial Metrics

Key Facts

• Special meeting to vote on merger set for July 13, 2026; record date June 5, 2026.
• XOMA shareholders receive $39.00 per share in cash plus one CVR per share tied to the Janssen litigation.
• Ligand Pharmaceuticals is acquiring XOMA in a transaction valued at ~$739M aggregate.
• Board unanimously recommends FOR all proposals and >44% of voting power pre-committed via support agreements (BVF holds 43.0%, insiders 1.3%).
• Perpetual preferred stock (Series A XOMAP and Series B XOMAO) to be redeemed pre-closing with all accrued dividends paid.
• CVRs are non-transferable, not listed, highly contingent on the outcome of the Janssen litigation, and may have zero value.
• Merger requires approval of a majority of outstanding common shares, so abstentions/broker non-votes count as 'against'.
• Dissenters' rights available under Nevada law for common shareholders who do not vote in favor and comply with statutory procedures.
• Leerink Partners rendered fairness opinion that $39.00 cash consideration is fair from a financial point of view.
• Termination fee of $40 million payable by XOMA in certain circumstances.
• Expected close in Q3 2026; Hart-Scott-Rodino waiting period is a closing condition.

Financial Impact

Aggregate deal value ~$739M based on 17.7M shares × $39.00. Shareholders also receive CVRs with uncertain value tied to the Janssen patent litigation.

Risk Factors

• CVRs may have zero value if the Janssen litigation is unsuccessful or takes years to resolve.
• Failure to obtain regulatory approvals or stockholder approval could block or delay the merger.
• Merger agreement limits XOMA's ability to solicit alternative proposals; $40M termination fee may deter competing bids.
• If the merger fails, XOMA's stock may trade down meaningfully with lost premium and the cost of proxy/transaction expenses.
• Preferred shareholders who do not tender will have their shares forcibly redeemed; timing of redemption could affect dividend accrual.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

US Market Status

Related Tickers